Perrigo Sets Strategy For Global Infant Formula Growth
This article was originally published in The Tan Sheet
Executive Summary
The private labeler’s more than 60 planned product launches include Codex-compliant infant formulas. The firm also sees marketing formula in plastic containers as a U.S. sales driver.
You may also be interested in...
Perrigo Eyes $115 Bil. Worth Of Rx-To-OTC Switches On The Horizon
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition
Perrigo takes the next step toward becoming a one-stop shop for private-label consumer health products with its $808 million acquisition of infant formula and baby food firm PBM Holdings Inc
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.